Nicolas Coudurier – CEO, Biocodex
Biocodex has evolved from a pioneering French laboratory built around a single yeast strain into an international healthcare group spanning microbiota, women’s health and a focused orphan-disease activity. In this…
One of the special features of INNOTHERA, lies in its dual competency: pharmaceutical products and medical textiles. These two areas of expertise complement each other in a harmonious way and work towards the same end, that of treating common daily pathologies, such as venous disease. INNOTHERA’s pharmaceutical laboratory activity enables the Group to apply scientific knowledge and strict pharmaceutical processes to the medical textiles sector, thereby giving it a major advantage over its competitors.
Thanks to its human touch, INNOTHERA can concentrate its efforts on meeting assignments promptly and on achieving an excellent response rate, which is absolutely needed for managing the diversity of profiles and cultures within the group.
Currently, the INNOTHERA Group’s production is 100 % French, with exports amounting to more than 65 % of total sales, and covering more than 100 countries.
This is the price of a disciplined organisation and industrial process perfectly mastered that Innothera products in its French factories more than 20 drugs, controls 15 different dosage forms and distributes medicines in more than 100 countries.
Contact
Web: innothera.fr/en/
Biocodex has evolved from a pioneering French laboratory built around a single yeast strain into an international healthcare group spanning microbiota, women’s health and a focused orphan-disease activity. In this…
Nicolas Dufourt leads ALK France as General Manager, drawing on nearly two decades of tenure with the Danish allergy immunotherapy specialist. Under his stewardship, the French affiliate, comprising approximately 400…
France is reshaping its approach to obesity at a moment when scientific understanding, clinical practice and public expectations are all shifting. Dr Rudy Caillet offers a clear view of how…
With France at the forefront of rare disease expertise yet increasingly challenged on patient access, Amicus Therapeutics finds itself at the heart of both progress and paradox. In this interview,…
France has long been held up as Europe’s reference point for rare disease care – the first EU country with a national plan, a pioneer of coordinated expert networks, and…
With over two decades of international experience in the pharmaceutical industry, Olivier Zambelli brings both strategic vision and a deeply human approach to his role as President and General Manager…
With over 35 years of experience across major pharmaceutical markets, Corinne Blachier-Poisson, General Manager of Amgen France, she discusses Amgen France’s ambitions and the company’s pivotal role in shaping France’s…
After two decades with AstraZeneca across Europe and the United States, Anne-Laure Dreno now leads the group’s French affiliate at a time of exceptional scientific and organisational momentum. In this…
Launched in 2022 under the France 2030 biocluster programme, the Paris-Saclay Cancer Cluster (PSCC) is rapidly positioning itself as a new epicentre for oncology innovation in Europe. Under the leadership…
Founded in 1973, IFIS stands at the intersection of education, industry, and public policy, shaping the capabilities that underpin France’s global health leadership. Evolving from its origins as a training…
France is undergoing a quiet industrial renaissance in biomanufacturing, driven by a growing alignment between science, innovation, and policy. At the centre of this movement stands Laurent Lafferrère, CEO of…
With France now a cornerstone of its global strategy, Regeneron is accelerating its European expansion under the leadership of Antoine Catton. In less than two years, the affiliate has built…
See our Cookie Privacy Policy Here
